145 related articles for article (PubMed ID: 21069962)
1. Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
Kmentova I; Sutherland HS; Palmer BD; Blaser A; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA; Thompson AM
J Med Chem; 2010 Dec; 53(23):8421-39. PubMed ID: 21069962
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
Palmer BD; Thompson AM; Sutherland HS; Blaser A; Kmentova I; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
J Med Chem; 2010 Jan; 53(1):282-94. PubMed ID: 19928920
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
Palmer BD; Sutherland HS; Blaser A; Kmentova I; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA; Thompson AM
J Med Chem; 2015 Apr; 58(7):3036-59. PubMed ID: 25781074
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
Blaser A; Palmer BD; Sutherland HS; Kmentova I; Franzblau SG; Wan B; Wang Y; Ma Z; Thompson AM; Denny WA
J Med Chem; 2012 Jan; 55(1):312-26. PubMed ID: 22148391
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
Thompson AM; Blaser A; Anderson RF; Shinde SS; Franzblau SG; Ma Z; Denny WA; Palmer BD
J Med Chem; 2009 Feb; 52(3):637-45. PubMed ID: 19099398
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine (PA-824).
Thompson AM; Sutherland HS; Palmer BD; Kmentova I; Blaser A; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
J Med Chem; 2011 Oct; 54(19):6563-85. PubMed ID: 21846109
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824.
Li X; Manjunatha UH; Goodwin MB; Knox JE; Lipinski CA; Keller TH; Barry CE; Dowd CS
Bioorg Med Chem Lett; 2008 Apr; 18(7):2256-62. PubMed ID: 18358721
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships.
Kim P; Kang S; Boshoff HI; Jiricek J; Collins M; Singh R; Manjunatha UH; Niyomrattanakit P; Zhang L; Goodwin M; Dick T; Keller TH; Dowd CS; Barry CE
J Med Chem; 2009 Mar; 52(5):1329-44. PubMed ID: 19209893
[TBL] [Abstract][Full Text] [Related]
9. 7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.
Thompson AM; O'Connor PD; Marshall AJ; Yardley V; Maes L; Gupta S; Launay D; Braillard S; Chatelain E; Franzblau SG; Wan B; Wang Y; Ma Z; Cooper CB; Denny WA
J Med Chem; 2017 May; 60(10):4212-4233. PubMed ID: 28459575
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles.
Kim P; Zhang L; Manjunatha UH; Singh R; Patel S; Jiricek J; Keller TH; Boshoff HI; Barry CE; Dowd CS
J Med Chem; 2009 Mar; 52(5):1317-28. PubMed ID: 19209889
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis.
Upton AM; Cho S; Yang TJ; Kim Y; Wang Y; Lu Y; Wang B; Xu J; Mdluli K; Ma Z; Franzblau SG
Antimicrob Agents Chemother; 2015 Jan; 59(1):136-44. PubMed ID: 25331696
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824).
Cherian J; Choi I; Nayyar A; Manjunatha UH; Mukherjee T; Lee YS; Boshoff HI; Singh R; Ha YH; Goodwin M; Lakshminarayana SB; Niyomrattanakit P; Jiricek J; Ravindran S; Dick T; Keller TH; Dartois V; Barry CE
J Med Chem; 2011 Aug; 54(16):5639-59. PubMed ID: 21755942
[TBL] [Abstract][Full Text] [Related]
13. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
Chaudhari HK; Pahelkar A
Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure-activity relationships of antitubercular 2-nitroimidazooxazines bearing heterocyclic side chains.
Sutherland HS; Blaser A; Kmentova I; Franzblau SG; Wan B; Wang Y; Ma Z; Palmer BD; Denny WA; Thompson AM
J Med Chem; 2010 Jan; 53(2):855-66. PubMed ID: 19968290
[TBL] [Abstract][Full Text] [Related]
15. Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution.
Anderson RF; Shinde SS; Maroz A; Boyd M; Palmer BD; Denny WA
Org Biomol Chem; 2008 Jun; 6(11):1973-80. PubMed ID: 18480913
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and anti-tubercular activity of 2-nitroimidazooxazines with modification at the C-7 position as PA-824 analogs.
Kang YG; Park CY; Shin H; Singh R; Arora G; Yu CM; Lee IY
Bioorg Med Chem Lett; 2015 Sep; 25(17):3650-3. PubMed ID: 26199118
[TBL] [Abstract][Full Text] [Related]
17. Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
Thompson AM; O'Connor PD; Marshall AJ; Blaser A; Yardley V; Maes L; Gupta S; Launay D; Braillard S; Chatelain E; Wan B; Franzblau SG; Ma Z; Cooper CB; Denny WA
J Med Chem; 2018 Mar; 61(6):2329-2352. PubMed ID: 29461823
[TBL] [Abstract][Full Text] [Related]
18. 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases.
Thompson AM; Blaser A; Palmer BD; Anderson RF; Shinde SS; Launay D; Chatelain E; Maes L; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
Bioorg Med Chem Lett; 2017 Jun; 27(11):2583-2589. PubMed ID: 28462832
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids.
Rakesh ; Bruhn DF; Scherman MS; Singh AP; Yang L; Liu J; Lenaerts AJ; Lee RE
Bioorg Med Chem Lett; 2016 Jan; 26(2):388-391. PubMed ID: 26711150
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, structure and biological evaluation of novel bicyclic nitroimidazole derivatives.
Zaprutko L; Zwawiak J; Augustynowicz-Kopeć E; Zwolska Z; Bartoszak-Adamska E; Nowicki W
Arch Pharm (Weinheim); 2012 Jun; 345(6):463-7. PubMed ID: 22266946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
